154P - Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Hong-Fei Gao
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors H. Gao, Y. Wu, J. Yang, X. Zhang
  • Guangdong Lung Cancer Institute, Guangdong General Hospital, 510080 - Guangzhou/CN

Abstract

Background

The activation of c-Met has been associated with both primary and acquired resistance to EGFR-TKI therapy in NSCLC patients. It suggested c-Met status during EGFR-TKI therapy should be concerned.

Methods

We retrospectively investigated the dynamic change of soluble c-Met level in plasma and the relationship with the clinical outcomes of EGFR-TKI therapy in advanced NSCLC patients. Immunohistochemistry (IHC) was used to assess the expression of c-Met in the resistant tissue. Plasma c-Met levels were assayed in duplicate using a human soluble c-Met quantitative enzyme-linked immunosorbent assay (ELISA) kit.

Results

A total of 49 advanced NSCLC patients with EGFR-TKI resistance were selected for the present study. When PD, IHC results showed 37(75.5%) of the patients were tissue c-Met negative, 12 (24.5%) were tissue c-Met positive. There was statistically significant difference in dynamic change of soluble c-Met between tissue c-Met negative group and c-Met positive group (P = 0.002). Patients with baseline soluble c-Met levels >766 ng/ml showed an inferior median PFS (10.2 vs. 14.0 months, P = 0.003) after EGFR-TKI. Multivariate Cox proportional hazards model analyses demonstrated soluble c-Met level was the independent prognostic factor for PFS after EGFR-TKI (P = 0.009, HR 3.583, 95% CI, 1.379–9.312).

Conclusions

uble c-Met in plasma by ELISA provided a non-invasive and sensitive assay to predict EGFR-TKI prognosis.

Clinical trial identification

Legal entity responsible for the study

Guangdong Lung Cancer Institute

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.